Though epigenetic regulators such as ASXL1 are frequently affected by mutations, all in all, EZH2 mutations seem to be rare events in CML [33,37,38]. This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.